Literature DB >> 24126938

Studies on the role of osteopontin-1 in endometrial cancer cell lines.

J C Hahne1, S R Meyer, P Kranke, J Dietl, M Guckenberger, B Polat, A Hönig.   

Abstract

BACKGROUND: Osteopontin-1 is a well characterized protein in many tumour entities. Multiple roles in the processes invasion, metastasis and angiogenesis of tumours are attributed to osteopontin-1. The putative role of osteopontin-1 has not been characterized for endometrial cancer.
MATERIAL AND METHODS: We investigated multiple endometrial cancer cell lines for osteopontin-1 mRNA- and protein-expression. Osteopontin-1 dependent effects were analysed in vitro by siRNA inhibition.
RESULTS: All endometrial cell lines expressed osteopontin-1. Expression of osteopontin-1 was successfully inhibited by specific siRNA. Cells with reduced osteopontin-1 expression showed decreased migration in the Boyden chamber assay and invasion was reduced in the wound-healing assay. Osteopontin-1 seems to play a role in apoptotic processes of endometrial cancer cells. Inhibition of osteopontin-1 expression was associated with an increased susceptibility for radiation therapy.
CONCLUSION: Osteopontin-1 seems to play a role in endometrial cancer. Inhibition of osteopontin-1 expression leads to a higher susceptibility for radiation therapy. Our results suggest that a reduced expression of osteopontin-1 in endometrial cancer could inhibit the development of invasion and metastasis in these cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24126938     DOI: 10.1007/s00066-013-0434-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  33 in total

1.  The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway.

Authors:  Y H Lin; H F Yang-Yen
Journal:  J Biol Chem       Date:  2001-10-05       Impact factor: 5.157

2.  MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research.

Authors:  James M Rae; Chad J Creighton; Jeanne M Meck; Bassem R Haddad; Michael D Johnson
Journal:  Breast Cancer Res Treat       Date:  2006-09-27       Impact factor: 4.872

3.  Ultrasound-guided interstitial brachytherapy in the treatment of advanced vaginal recurrences from cervical and endometrial carcinoma.

Authors:  Hajo Dirk Weitmann; Tomas Hendrik Knocke; Claudia Waldhäusl; Richard Pötter
Journal:  Strahlenther Onkol       Date:  2006-02       Impact factor: 3.621

4.  Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion.

Authors:  Abdullah Karadag; Kalu U E Ogbureke; Neal S Fedarko; Larry W Fisher
Journal:  J Natl Cancer Inst       Date:  2004-06-16       Impact factor: 13.506

5.  Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells.

Authors:  Aimin Zhang; Yi Liu; Yizheng Shen; Youhe Xu; Xiangtie Li
Journal:  Med Oncol       Date:  2009-11-17       Impact factor: 3.064

6.  Receptor-ligand interaction between CD44 and osteopontin (Eta-1).

Authors:  G F Weber; S Ashkar; M J Glimcher; H Cantor
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

7.  Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation.

Authors:  D R Senger; C A Perruzzi; C F Gracey; A Papadopoulos; D G Tenen
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

Review 8.  Current issues in the management of endometrial cancer.

Authors:  Jamie N Bakkum-Gamez; Jesus Gonzalez-Bosquet; Nadia N Laack; Andrea Mariani; Sean C Dowdy
Journal:  Mayo Clin Proc       Date:  2008-01       Impact factor: 7.616

9.  Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy.

Authors:  Timothy D Solberg; Jessica Nearman; John Mullins; Sicong Li; Janina Baranowska-Kortylewicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-01       Impact factor: 7.038

10.  [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance].

Authors:  Li-Li Zhang; Shu-Li Shao; Yan Wu
Journal:  Chin J Cancer       Date:  2010-01
View more
  3 in total

1.  Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinoma.

Authors:  Xinqiong Huang; Yujie Qian; Hainan Wu; Xiaoxue Xie; Qin Zhou; Ying Wang; Weilu Kuang; Lin Shen; Kai Li; Juan Su; Liangfang Shen; Xiang Chen
Journal:  J Histochem Cytochem       Date:  2014-11-07       Impact factor: 2.479

2.  Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines.

Authors:  Gisela Wohlleben; Agmal Scherzad; Antje Güttler; Dirk Vordermark; Sebastian Kuger; Michael Flentje; Buelent Polat
Journal:  Radiat Oncol       Date:  2015-08-12       Impact factor: 3.481

Review 3.  Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Tingting Sun; Peng Li; Diwen Sun; Qingao Bu; Guoqiang Li
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.